Product Pipeline

Our priority indications

Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
PBI-4050
Idiopathic Pulmonary Fibrosis
PBI-4050
Alström Syndrome
Ryplazim™ IV
Congenital Deficiency
PBI-4547
Nonalcoholic Steatohepatitis (NASH)